. (2022). Low- and Very Low-Dose Bevacizumab for Retinopathy of Prematurity: Reactivations, Additional Treatments, and 12-Month Outcomes. Ophthalmology, 129(10), 1120-1128. 10.1016/j.ophtha.2022.05.019 (Original work published 2022)
Deborah VanderVeen
. (2020). Short-term Outcomes After Very Low-Dose Intravitreous Bevacizumab for Retinopathy of Prematurity. Jama Ophthalmology, 138(6), 698-701. 10.1001/jamaophthalmol.2020.0334 (Original work published 2020)
. (2017). Assessment of Lower Doses of Intravitreous Bevacizumab for Retinopathy of Prematurity: A Phase 1 Dosing Study. Jama Ophthalmology, 135(6), 654-656. 10.1001/jamaophthalmol.2017.1055 (Original work published 2017)
. (2011). Prevalence and course of strabismus through age 6 years in participants of the Early Treatment for Retinopathy of Prematurity randomized trial. Journal Of The American Association For Pediatric Ophthalmology And Strabismus (J Aapos), 15(6), 536-40. 10.1016/j.jaapos.2011.07.017 (Original work published 2011)
. (2006). Prevalence and course of strabismus in the first year of life for infants with prethreshold retinopathy of prematurity: findings from the Early Treatment for Retinopathy of Prematurity study. Archives Of Ophthalmology, 124(6), 766-73. 10.1001/archopht.124.6.766 (Original work published 2006)